All News

Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

The FDA today posted warning letters issued to 2 companies for the illegal marketing of products labeled as dietary supplements that contain tianeptine, a chemical compound that companies are illegally claiming treats opioid use disorder (OUD), pain and anxiety, and other unlawful and unproven claims.

The change aims to reinforce joint product development targets, accelerate the CGM products developer's efforts in type 2 diabetes, and improve its long-term profitability

Officials with the FDA have approved emapalumab (Gamifant) for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH), making it the first FDA-approved drug specifically indicated for this disease.

Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.

Study identifies potential biomarkers that could provide a quicker path to diagnosis of amyotrophic lateral sclerosis.

Eli Lilly has submitted a New Drug Application (NDA) to the FDA for lasmiditan for the acute treatment of migraine with or without aura in adults.

Top news of the day from across the health care landscape.

New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

Lasmiditan’s mechanism is distinct from other therapies and, if approved, represents significant innovation in the acute treatment of migraine.

A new study shows high prevalence of atopic dermatitis among adults, illustrating the need for more available treatment options.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

The FDA has approved lamivudine and tenofovir disoproxil fumarate (Temixys, Celltrion) tablets, 300 mg/300 mg in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.

he FDA has expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy (IST) to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Rifamycin's effectiveness was shown in a randomized, placebo-controlled clinical trial during which the drug significantly reduced symptoms of travelers’ diarrhea in adults afflicted with the condition in Guatemala and Mexico.

When fish oils are given to the general public, there was not a reduction of major cardiovascular events. Among subgroups, differences were noted.